Real-World Data Back Immunotherapy in Stage III Melanoma

(MedPage Today) -- Treatment with adjuvant immunotherapy conferred a survival advantage for patients with resectable melanoma at the highest risk of relapse, real-world evidence from the National Cancer Database (NCDB) showed.
Among over 4,000...